---
figid: PMC9650589__fphar-13-1018480-g005
pmcid: PMC9650589
image_filename: fphar-13-1018480-g005.jpg
figure_link: /pmc/articles/PMC9650589/figure/F5/
number: FIGURE 5
figure_title: ''
caption: 'Eldecalcitol exerts its activity by inhibiting FOXO1 and FOXO3 transcription
  factors and promoting PI3K/AKT signaling pathways. (A,B) The mRNA levels of FOXO1nad
  FOXO3. (C–E) The protein levels of P-PI3K, PI3K and P-AKT. *p < 0.05 versus sham;
  **p < 0.01 versus sham; #p < 0.05 versus ORX; ##p < 0.01 versus ORX. Data are expressed
  as mean ± SEM, n ≥ 3. Abbreviations: ELD, eldecalcitol; ORX, orchiectomy; GADPH,
  Glyceraldehyde-3-Phosphate Dehydrogenase; PI3K, Phosphoinositide 3-kinases; P-AKT,
  phosphorylated AKT; SEM, standard error of mean.'
article_title: Eldecalcitol prevents muscle loss by suppressing PI3K/AKT/FOXOs pathway
  in orchiectomized mice.
citation: Haichao Zhang, et al. Front Pharmacol. 2022;13:1018480.
year: '2022'

doi: 10.3389/fphar.2022.1018480
journal_title: Frontiers in Pharmacology
journal_nlm_ta: Front Pharmacol
publisher_name: Frontiers Media S.A.

keywords:
- bone strength
- eldecalcitol
- muscle atrophy
- ORX
- PI3K/AKT/FOXOs

---
